Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Shenogen Pharma In-licenses Alopexx Fusion CD20 Protein for Lymphoma

publication date: Mar 4, 2020

Beijing Shenogen Pharma in-licensed China-Asia rights from Alopexx Oncology of Massachusetts to a novel antibody-cytokine fusion protein (or immunocytokine) that targets the B cell antigen CD20. It is aimed at treating patients with relapsed or refractory B-cell CD20 positive lymphoma. DI-LEU16-IL2 recognizes the same target on B cells as Rituxan and maintains the activities of both the antibody and cytokine components. It is also expected to target the tumor, engage the immune system and induce a cancer-fighting vaccine effect. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital